-

ZOLL Reports Recent Data Security Incident

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL is notifying affected individuals of a data security incident that occurred on January 28, 2023. ZOLL confirmed on February 2, 2023 that an unauthorized third party may have obtained access to some individuals’ protected health information. The PHI may have included some individuals’ names, addresses, dates of birth, some Social Security numbers and information that may allow one to infer that the individual used or was considered for use of the ZOLL LifeVest® wearable cardioverter defibrillator (WCD). ZOLL has no indication that the information has been misused. ZOLL is evaluating its security measures. ZOLL is notifying affected individuals by mail. Individuals with questions can contact a dedicated call center at 800-459-5782 Monday through Friday from 8 am to 10 pm CST and Saturday and Sunday from 10 am to 7 pm CST.

Contacts

Matt Hogan
ZOLL
+1 (978) 805-6561
media@zoll.com

ZOLL


Release Versions

Contacts

Matt Hogan
ZOLL
+1 (978) 805-6561
media@zoll.com

More News From ZOLL

ZOLL® Expands “Anything Can Happen. Anyone Can Help.”™ to Strengthen Cardiac Emergency Readiness Across Youth Sports Nationwide

CHELMSFORD, Mass.--(BUSINESS WIRE)--From local fields to national venues, youth sports play out every day across the country. Today, ZOLL® Medical, an Asahi Kasei company, announced the next phase of its national Anything Can Happen. Anyone Can Help.™ campaign, aimed at strengthening cardiac emergency readiness where young athletes play. Sudden cardiac arrest remains the leading cause of death among young athletes1, and approximately 356,000 out-of-hospital cardiac arrests occur nationwide each...

New Data: LifeVest® Wearable Defibrillator is Useful Tool for Quicker Beta-Blocker Optimization in Women

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced that insights from the LifeVest® wearable cardioverter defibrillator (WCD) helped physicians achieve better heart rate control in female patients – an indicator of more rapid beta-blocker optimization and an outcome associated with improved survival. These findings come from the Optimizing Beta‑Blocker Dosage in Female Patients Using the Wearable Cardiove...

Sudden Cardiac Death Risk and Heart Failure Management at ACC.26 – How ZOLL Innovations Redefine Protection

CHELMSFORD, Mass.--(BUSINESS WIRE)--ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, will highlight the latest sudden cardiac death research, case experiences for heart failure readmission reduction, and two Innovation Stage presentations at the American College of Cardiology Annual Scientific Session & Expo (ACC.26), March 28-30, 2026. ZOLL will sponsor a slate of educational programs to engage and connect clinicians with emerging evidence and...
Back to Newsroom